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Live birth from a 46-year-old using
fresh autologous oocytes through
in vitro fertilization*
Mark P. Trolice, M.D.
Fertility Center of Assisted Reproduction and Endocrinology, Winter Park, FloridaObjective: To report a live birth with IVF from a 46-year-old woman using autologous oocytes.
Design: Case report.
Setting: Reproductive endocrinology and infertility private practice and ambulatory IVF center.
Patient(s): One 46-year-old nulligravid woman.
Intervention(s): IVF with fresh ET.
Main Outcome Measure(s): Live birth after IVF.
Result(s): A 46-year-old with antimullerian hormone (AMH) level less than 0.16 conceived through IVF using autologous oocytes.
A total of seven oocytes were retrieved, from which four embryos were transferred at the cleavage stage, resulting in a pregnancy
and delivery of a healthy male infant weighing 1,580 g at 31 and 3/7 weeks' estimated gestational age.
Conclusion(s): The prognosis for a live birth from IVF in a patient with very advanced reproductive age, particularly with an unde-Use your smartphonetectable AMH level using autologous oocytes, remains extremely poor. This case should be in-
terpreted with caution so as to not provide false hope to women aged 45 and above. (Fertil
Steril 2014;102:96–8. 2014 by American Society for Reproductive Medicine.)
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scanner” in your smartphone’s app store or app marketplace.eproductive aging refers to theR natural depletion of the en-dowed cohort of oocytes in a
woman and is inherently related to
decreasing ovarian reserve (DOR). Bio-
logically inevitable for women, DOR
describes the waning ability of a
reproductive-age woman to conceive
and the decreased response to gonado-
tropin ovarian stimulation compared
with age-matched controls (1). Ovarian
reserve tests have been designed to
indirectly assess the quantity of oocytes
within the ovary with the goal to pre-
dict pregnancy success. While ovarian
age markers such as antimullerian hor-Received January 29, 2014; revised and accepted Ap
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96mone (AMH) and antral follicle count
by pelvic sonogram have not been
shown to accurately predict which
patients will experience a live birth
from IVF, poor test results have resulted
in a decreased number of oocytes
retrieved (1).
The percentage of women delaying
childbearing continues to increase, and
approximately 20% of women remain
childless, doubling from 30 years prior
(2). Reproductive aging varies markedly
among women, with some maintaining
fertility in the ﬁfth decade of life and
others becoming infertile in their
midthirties (3).ril 9, 2014; published online May 3, 2014.
ND license (http://creativecommons.org/licenses/
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Inc.DOR remains a signiﬁcant challenge
for reproductive clinicians to manage
effectively. Currently, no gonadotropin
stimulation method with pituitary sup-
pression has shown superiority in poor
responding patients (4). Nevertheless,
there is no deﬁned upper age limit for
completely eliminating the chance of
success in a premenopausal woman us-
ing autologous oocytes through assisted
reproductive technology.
In a review of studies, most women
over 45 years of age have healthy preg-
nancy outcomes and are able to meet
the challenges of pregnancy and child
rearing (5–8). The most common
complications in the pregnancies of
older gravid patient involve
hypertension and diabetes, both of
which are worsened in the overweight
patient.
We present a successful live birth to a
46-year-old nulliparous woman using
autologous oocytes with IVF and fresh ET.VOL. 102 NO. 1 / JULY 2014
Fertility and Sterility®MATERIALS AND METHODS
This is a case report of a patient at our reproductive endocri-
nology and infertility private practice and ambulatory IVF
center. We performed an extensive Medline search with key
words ‘‘IVF outcome, autologous oocytes, advanced maternal
age, and live birth.’’ No Institutional Review Board (IRB)
approval was obtained. Our IRB designates a single-patient
case report as not subject to IRB review because it does not
meet the deﬁnition of human subjects research.RESULTS
The patient is a nulliparous female who initially presented at
44 years of age with infertility and bilateral proximal tubal
occlusion on a recent hysterosalpingogram. Her history is
remarkable for one prior elective termination, abdominal
myomectomy, and hysteroscopy myomectomy. Two years
later she proceeded with IVF, undergoing oocyte retrieval at
46 years and 85 days of age, conﬁrmed by state-issued
driver's license. Precycle evaluation included consultation
with maternal fetal medicine, electrocardiogram, chest
X-ray, 2-hour glucose tolerance test, and exercise treadmill
test. Her ovarian age testing revealed an antral follicle count
of 5 and AMH level of<0.16 ng/mL. After combined oral con-
traceptives for 10 days, she was placed on letrozole 5 mg
orally daily for 5 days and recombinant FSH 300 IU SC daily
beginning on day 2 of letrozole. On stimulation day 5, serum
E2 was 60 pg/mL, P was 1.72 ng/mL, and a lead follicle devel-
oped with ameanmeasurement of 15.5mm. GnRH antagonist
(ganirelix) 250 mg SC daily was initiated, and by stimulation
day 9, E2 was 265 pg/mL, P was 1.7 ng/mL, endometrium
thickness measured 10.18 mm, and lead follicle measured aFIGURE 1
Four grade IV embryos transferred on day 3: two at 7-cell stage, one at 6-
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mm. HCG 10,000 IU IM was prescribed followed by oocyte
retrieval 36 hours thereafter. A total of seven oocytes were
retrieved, of which four embryos were available on day 3
for transfer after assisted hatching: two embryos were at the
7-cell stage, one at the 6-cell stage, and one at the 4-cell stage,
all with morphologic grade 4 (on the scale of 1–5; Fig. 1). ET
was performed without difﬁculty under abdominal ultra-
sound guidance using the 18 cm Wallace Sure View Embryo
Replacement Catheter (CE118) to a depth measuring 2 cm
from the fundus. No remaining embryos were available for
cryopreservation. Luteal support was achieved with trans-
dermal E2 0.1 mg two patches changed twice weekly and IM
P in oil 50 mg daily converted to micronized P 200mg vaginal
three times a day with pregnancy and discontinued at 12
weeks of gestation. She declined preimplantation genetic
screening (PGS) for comprehensive chromosome screening
(CCS) of embryos. Serum beta-hCG at 14 days post-ET was
300 mIU/mL. Obstetrical sonogram revealed a single viable
intrauterine pregnancy appropriate for a gestational age at
7 weeks. Antepartum aneuploidy screening with integrated
screen showed an increased risk of trisomy 21 of 1:33. The pa-
tient declined amniocentesis and underwent Panorama test
revealing a low risk for trisomy 21, 18, and 13. At 21 weeks'
gestation, she presented to her obstetrician with mild lower
abdominal pressure. On pelvic examination she had a 4 cm
dilated cervix with bulging membranes prompting rescue
cerclage. At 28 weeks' gestation she developed preterm pre-
mature rupture of membranes. Owing to variable fetal heart
rate decelerations, a cesarean section was performed at 31
weeks' gestation of a male infant weighing 1,580 g who re-
mains thriving at 4 months of age.cell stage, and one at 4-cell stage.
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This is the ﬁrst report of successful live birth from IVF in a 46-
year-old woman using autologous oocytes by gonadotropin
stimulation. In addition to a very advanced reproductive
age, our patient had an AMH level that was undetectable.
Only one other report describes a woman who achieved a
live birth at the same age as our patient but who used clomi-
phene citrate 150 mg stimulation for 5 days, resulting in three
oocytes retrieved and one fertilized with transfer of a 2-cell
embryo (9). Spandorfer et al. reported on 288 IVF cycles in
women age 45–49 and found a 3.1% overall delivery rate
but only in women at a maximum age of 45 years who pro-
duced greater than ﬁve oocytes (10).
Women in their midforties with infertility are essentially
faced with three options: using autologous oocytes, using an
egg donor, or adoption. While family building is far more suc-
cessfully achieved with the latter two options, many women
strongly desire a biologically related child. The option ulti-
mately selected by the patient is personal but is not inﬂuenced
by gender, years of infertility, or religion (11).
Pregnancy complications increase in women with
advanced reproductive age, particularly in those who are
nulliparous, and include caesarean section, gestational dia-
betes, preeclampsia, placenta previa, placenta abruption, still-
birth, low birth weight, and premature rupture of membranes
with preterm delivery as occurred in our patient (7, 12).
In women of advanced reproductive age, the risk of aneu-
ploidy in embryos may exceed 60%, thereby signiﬁcantly
contributing to declining embryo implantation rates (13).
PGS with CCS of embryos has shown promise in reducing
miscarriage and improving pregnancy success rates (14).
Because of the expected poor response to gonadotropin stim-
ulation, our patient deferred PGS.
The risk of aneuploidy from a spontaneous pregnancy at
age 46 is estimated at 1 in 23 for trisomy 21 and 1 in 16 for
any aneuploidy (15). Our patient underwent antepartum
aneuploidy testing, revealing a low risk for chromosomal
abnormalities.
Currently, there is no intervention clinically proven to
improve the prognosis of a live birth in a patient who is a
poor responder. A meta-analysis by Kyrou et al. suggested
that the addition of growth hormone during stimulation
and performing a day 2 versus day 3 ET may improve the
outcome (16). Neither of these methods was used with our
patient.
After oocyte retrieval, there is always the potential risk of
spontaneous pregnancy through periovulatory intercourse.
While this occurrence is plausible, we consider this unlikely
in our patient owing to several reasons. On the day of hCG98trigger, there were eight dominant ovarian follicles above
10 mm, including a premature lead follicle measuring 41
mm. Oocyte retrieval resulted in seven oocytes with the pre-
sumed exception of the lead follicle. Additionally, we instruct
our patients to avoid intercourse after oocyte retrieval. Lastly,
the patient was diagnosed with bilateral tubal occlusion. As a
result, we believe our patient conceived through ET.
This case should be interpreted with caution so as to not
provide false hope to women aged 45 and above. The prog-
nosis for a live birth from IVF in a patient with advanced
reproductive age, particularly with an undetectable AMH
level, using autologous oocytes remains poor but cannot be
considered futile in women 46 years of age and younger.
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